It is known that the degree of hypoxia/HIF-1 or lactate content within the tumor microenvironment is obviously different in different tumor types or tumor stages, which may lead to differences in the expression of m6A mRNA modification regulators and real-time changes, as well as differences in the therapeutic efficacy of targeted m6A. Therefore, all of these reports suggest that we should pay attention to not only the downstream mechanism of m6A regulation, but also the effect of targeted m6A therapy. The gene discussed is HIF1A; the disease is neoplasm.